EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 3.0

The Study of PIK3CA Hotspot Mutations and Co-Occurring with EGFR, KRAS, and TP53 Mutations in Non-Small Cell Lung Cancer

YuXuan Zhang, Yuhong Shen iD, Jiayuan Wu, Jun Zhang, Chenxi Cao, Juanfen Mo, Yi Bao

OncoTargets and Therapy · 2024-09 · Volume 17 · 755-763

DOI: 10.2147/ott.s468352 ↗

At a glance

Journal article in OncoTargets and Therapy, 2024-09. Written by YuXuan Zhang and 6 co-authors. Institution: The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310000, People's Republic of China. Cited 7 times so far (Crossref); 27 references. The full text is freely available (open access, CC BY-NC 3.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

PIK3CA-mutant non-small-cell lung cancer (NSCLC) is associated with other genetic mutations and may influence treatment strategies and clinical outcomes. We aimed to characterize PIK3CA mutations co-occurring with several major driver mutations using data from published cohorts and our medical center. Materials and Methods: We analyzed NSCLC patients harboring PIK3CA mutations from The Cancer Genome Atlas (TCGA) and Memorial Sloan Kettering (MSK) databases and retrospectively identified NSCLC patients with PIK3CA-mutants at a single medical center from our electronic records. The Log rank test was used to determine the association between PIK3CA mutations and overall survival (OS) in NSCLC patients.

Results

Common hotspot mutations in PIK3CA were found in exon 9 (c.1633G > A, E545K, and c.1624G > A, E542K) and exon 20 (c.3140A > G, H1047R) in all cohorts. Co-occurring mutations of PIK3CA with EGFR, KRAS, and TP53 have been frequently observed in patients with NSCLC, with different percentages in these datasets generated by different background. PIK3CA mutations were observed to be significantly associated with poor OS in lung adenocarcinomas patients in the MSKCC cohort (hazard ratio [HR] = 0.519, 95% confidence interval [CI] = 0.301-0.896; P

Subjects

Author keywords

Memorial Sloan Kettering Cancer CenterPIK3CAThe Cancer Genome Atlasco-occurring mutationnon-small cell lung cancer

Authors and institutions

  • The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310000, People's Republic of China.
  • The Key Laboratory, the Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, People's Republic of China.
  • Transfusion Center, the Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, People's Republic of China.
  • The Department of Thoracic Surgery, the Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, People's Republic of China.
  • The Department of Oncology, the Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, People's Republic of China.

ORCID profiles: Yuhong Shen

Cite

APA

Zhang, Y., Shen, Y., Wu, J., Zhang, J., Cao, C., Mo, J., & Bao, Y. (2024). The Study of PIK3CA Hotspot Mutations and Co-Occurring with EGFR, KRAS, and TP53 Mutations in Non-Small Cell Lung Cancer. OncoTargets and Therapy, Volume 17, 755-763. https://doi.org/10.2147/ott.s468352

Vancouver

Zhang Y, Shen Y, Wu J, Zhang J, Cao C, Mo J, et al. The Study of PIK3CA Hotspot Mutations and Co-Occurring with EGFR, KRAS, and TP53 Mutations in Non-Small Cell Lung Cancer. OncoTargets and Therapy. 2024;Volume 17:755-763. doi:10.2147/ott.s468352

BibTeX
@article{Zhang2024,
  author = {Zhang, YuXuan and Shen, Yuhong and Wu, Jiayuan and Zhang, Jun and Cao, Chenxi and Mo, Juanfen and Bao, Yi},
  title = {The Study of PIK3CA Hotspot Mutations and Co-Occurring with EGFR, KRAS, and TP53 Mutations in Non-Small Cell Lung Cancer},
  journal = {OncoTargets and Therapy},
  year = {2024},
  volume = {Volume 17},
  pages = {755--763},
  doi = {10.2147/ott.s468352}
}
Start for free →